Steroid sparing agents for lupus

Measurement of anti-dsDNA antibodies, complements, and creatinine; a complete blood count; and urinalysis should be performed every three to six months to monitor disease activity. 8 Annual eye examinations are required for patients receiving hydroxychloroquine. 36 Screening for dyslipidemia, diabetes, and osteoporosis should be performed regularly in patients receiving glucocorticoids. For patients with chronic kidney disease who are receiving long-term immunosuppressive therapy, immunization with 13-valent pneumococcal conjugate vaccine (Prevnar) followed by 23-valent pneumococcal polysaccharide vaccine (Pneumovax) should be considered. 54   Live vaccines should not be given to patients with SLE when they are receiving immunosuppressive therapy, and they should be delayed for at least one month after completion of the therapy. Table 4 includes details for monitoring medications used in SLE treatment. 8 , 24 – 27 , 55 , 56

Steroid sparing agents for lupus

steroid sparing agents for lupus

Media:

steroid sparing agents for lupussteroid sparing agents for lupussteroid sparing agents for lupussteroid sparing agents for lupussteroid sparing agents for lupus